ImmunityBio said that its human Ad5 vaccine candidate (hAd5 vaccine candidate), which is being developed for the prevention of Covid-19, has yielded positive preclinical results.
Catalent has collaborated with speciality pharmaceutical company Ennaid Therapeutics for the development of an oral and antiviral treatment for Covid-19 disease.
Vir Biotechnology and Alnylam Pharmaceuticals said that they have selected an investigational RNAi therapeutic called VIR-2703 which will be developed for targeting the SARS-CoV-2 genome for the treatment of Covid-19 (novel coronavirus).
Hoth Therapeutics has reached an agreement with Voltron Therapeutics to form a joint venture entity, to be named HaloVax, to commence preclinical studies for the development of vaccine prospects to prevent the Coronavirus (COVID-19) based upon VaxCelerate.
Israeli biopharmaceutical firm RedHill Biopharma has secured the US Food and Drug Administration (FDA) approval for Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the treatment of Helicobacter pylori (H. pylori) infection in adults.
Neoleukin Therapeutics, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced the completion of the previously disclosed merger transaction with Aquinox Pharmaceuticals.
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida.
A new study in the UK has shown that EZH2, an epigenetic protein, can potentially be a new therapeutic target for the treatment of acute myeloid leukemia (AML).
UK based biotech company Redx said that its lead selective ROCK2 compound has been shown to have broad potential in the treatment of fibrosis as per new in vivo data.
Nash Pharmaceuticals, a subsidiary of Breathtec Biomedical, has announced that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM mouse model from SMC Laboratories.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.